Margrit Marti

Margrit Marti's practice focuses on mergers & acquisitions, private equity and venture capital. She also advises clients on IPOs and other equity capital markets transactions as well as in matters of corporate law, securities regulation and corporate governance.

• Advised VectivBio with respect to the public cash tender offer from Ironwood Pharmaceuticals (USD 1 billion)
• Advised Noema Pharma on its USD 112 million Series B financing round

• Advised AMF Medical and its shareholders on the USD 200 million sale to Tandem Diabetes Care

• Advised Credit Suisse Group (SIX: CSGN) in connection with share capital increases of CHF 4 billion
• Advised VectivBio (Nasdaq: VECT) on its USD 125 million underwritten offering, its USD 50 million follow-on public offering and concurrent private placement and its IPO on Nasdaq with a market capitalization of USD 824 m (at market close)

• Capital markets: Equity
• M&A
• Private equity

• Consumer goods and services
• Financial services
• Industrials
• Pharma and life sciences
• Tech and telecoms

• Swiss Bar Association 
• Zurich Bar Association
• International Bar Association

• LL.M., Certificate in Business Law, University of California, Berkeley (2015)

• M.A. HSG in Law, University of St. Gallen (2009)